Sekundäre Diabetesformen / Typ-3-Diabetes

Einleitung

Diagnostisch und therapeutisch unterscheiden sich die sekundären Diabetesformen zum Teil erheblich von den häufigen Formen des Diabetes, dem Typ-1-Diabetes, dem Typ-2-Diabetes und dem Gestationsdiabetes. Da oftmals eine kausale Therapie möglich ist, kommt neben der korrekten Differenzialdiagnose dem Wissen um die Spezifika dieser Diabetesformen eine wichtige Bedeutung zu. Ziel dieser Übersicht ist es, einige ausgewählte Formen des sekundären Diabetes hinsichtlich Pathogenese, Diagnostik und Therapie darzustellen. 

Literatur

• 1 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the expert committee on the diagnosis and classification of diabetes mellitus.  Diabetes Care. 1997;  20 1183-1197
• 2 Fajans S S, Bell G I, Polonsky K S. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.  NEJM. 2001;  345 971-980
• 3 Stumvoll M, Stefan N, Fritsche A et al. Diabetes mellitus. In: Lehnert H, Hrsg. Rationelle Diagnostik und Therapie in Endokrinologie, Stoffwechsel und Diabetes. Stuttgart: Thieme; 2009: 335–379
• 4 Hummel M, Vasseur F, Mathieu C et al. Two caucasian families with the hepatocyte nuclear factor-1alpha mutation Y218C.  Exp Clin Endocrinol Diabetes. 2007;  115 62-64
• 5 Moran A, Dunitz J, Nathan B et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.  Diabetes Care. 2009;  32 1626-1631
• 6 Moran A, Pekow P, Grover P Cystic Fibrosis Related Diabetes Therapy Study Group et al.,. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.  Diabetes Care. 2009;  32 1783-1788
• 7 Rizza R A, Mandarino L J, Gerich J E. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action.  J Clin Endocrinol Metab. 1982;  54 131-138
• 8 Biering H, Knappe G, Gerl H et al. [Prevalence of diabetes in acromegaly and Cushing’s disease].  Acta Medica Austriaca. 2000;  27 27-31
• 9 Arnaldi G, Mancini T, Polenta B et al. Cardiovascular risk in Cushing’s syndrome.  Pituitary. 2004;  7 253-256
• 10 Newell-Price J, Bertagna X, Grossman A B et al. Cushing’s syndrome.  Lancet. 2006;  367 1605-1617
• 11 Findling J W, Raff H. Cushing’s Syndrome: important issues in diagnosis and management.  J Clin Endocrinol Metab. 2006;  91 3746-3753
• 12 Whitworth J A, Williamson P M, Mangos G et al. Cardiovascular consequences of cortisol excess.  Vasc Health Risk Manag. 2005;  1 291-299
• 13 Colao A, Auriemma R S, Galdiero M et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.  J Clin Endocrinol Metab. 2009;  94 3746-3756
• 14 Ali O, Banerjee S, Kelly D F et al. Management of type 2 diabetes mellitus associated with pituitary gigantism.  Pituitary. 2007;  10 359-364
• 15 Møller N, Jørgensen J O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.  Endocr Rev. 2009;  30 152-177
• 16 Kasayama S, Otsuki M, Takagi M et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.  Clin Endocrinol (Oxf). 2000;  52 549-555
• 17 Resmini E, Minuto F, Colao A et al. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.  Acta Diabetol. 2009;  46 85-95
• 18 Yavuz D G, Yüksel M, Deyneli O et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.  Clin Endocrinol (Oxf). 2004;  61 515-521
• 19 Gupta A K, Dahlof B, Dobson J Anglo-Scandinavian Cardiac Outcomes Trial Investigators et al.,. Determinants of new-onset diabetes among 19 257 ypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.  Diabetes Care. 2008;  31 982-988
• 20 Elliott W J, Meyer P M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.  Lancet. 2007;  369 201-207
• 21 NAVIGATOR Study Group . Effect of valsartan on the incidence of diabetes and cardiovascular events.  N Engl J Med. 2010;  362 1477-1490
• 22 Basile J N. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease.  Int J Clin Pract. 2009;  63 656-666
• 23 Andersohn F, Schade R, Suissa S et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus.  Am J Psychiatry. 2009;  166 591-598
• 24 De Hert M, Schreurs V, Vancampfort D et al. Metabolic syndrome in people with schizophrenia: a review.  World Psychiatry. 2009;  8 15-22
• 25 American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes.  Diabetes Care. 2004;  27 596-601
• 26 Toro C, Jacobowitz D M, Hallett M. Stiff-Man Syndrome.  Sem Neurol. 1994;  14 154-158
• 27 Blum P, Jankovic J. Siff-Person Syndrome. An Autoimmune Disease.  Mov Disord. 1991;  6 2-20
• 28 Solimena M, Folli F, Aparisi R et al. Autoantibodies to GABA-ergic Neurones and Pancreatic Beta Cells in Stiff-Man Syndrome.  N Engl J Med. 1990;  322 1555-1560
• 29 Baekkeskov S, Aanstoot H J, Christgau S et al. Identification of the 64 k autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamatic acid decarboxylase.  Nature. 1990;  347 151-156
• 30 Hummel M, Durinovic-Bello I, Bonifacio E et al. Humoral and Cellular Immune Parameters before and during immunsuppressive therapy of a patient with Stiff-Man Syndrom and IDDM.  J Neurol Neurosurg Psychiatry. 1998;  65 204-208
• 31 Rohrer T R, Hennes P, Thon A DPV Initiative et al.,. Down’s syndrome in diabetic patients aged < 20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes.  Diabetologia. 2010;  53 1070-1075